GENFIT S.A. (GNFT): Price and Financial Metrics
GENFIT S.A. (GNFT)
Today's Latest Price: $4.47 USD
Updated Oct 23 4:00pm
Add GNFT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
GNFT Stock Summary
- Genfit SA's stock had its IPO on March 27, 2019, making it an older stock than only 2.53% of US equities in our set.
- Revenue growth over the past 12 months for Genfit SA comes in at 422.82%, a number that bests 98.35% of the US stocks we're tracking.
- The volatility of Genfit SA's share price is greater than that of 96.07% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to GNFT, based on their financial statements, market capitalization, and price volatility, are VNE, IPHA, IMOS, INFI, and HIMX.
- Visit GNFT's SEC page to see the company's official filings. To visit the company's web site, go to www.genfit.com.
GNFT Stock Price Chart Interactive Chart >
GNFT Price/Volume Stats
| Current price | $4.47 | 52-week high | $22.48 |
| Prev. close | $4.45 | 52-week low | $3.65 |
| Day low | $4.25 | Volume | 20,400 |
| Day high | $4.47 | Avg. volume | 78,382 |
| 50-day MA | $4.70 | Dividend yield | N/A |
| 200-day MA | $10.36 | Market Cap | 169.11M |
GENFIT S.A. (GNFT) Company Bio
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.
Loading social stream, please wait...